Total and mutated EGFR quantification in cell-free DNA from non-small cell lung cancer patients detects tumor heterogeneity and presents prognostic value

@article{Alegre2016TotalAM,
  title={Total and mutated EGFR quantification in cell-free DNA from non-small cell lung cancer patients detects tumor heterogeneity and presents prognostic value},
  author={Estibaliz Alegre and Juan Pablo Fusco and Patricia Restituto and Diego Salas-Benito and Mar{\'i}a Esperanza Rodr{\'i}guez-Ruiz and Maria Pilar Andueza and M. J. Pajares and Ana Pati{\~n}o-Garc{\'i}a and Rub{\'e}n P{\'i}o and Mar{\'i}a Dolores Ru{\'i}z Lozano and Alfonso G{\'u}rpide and Jos{\'e} Mar{\'i}a L{\'o}pez L{\'o}pez-Picazo and Ignacio Gil-Bazo and Jose Luis Perez-Gracia and {\'A}lvaro Gonzalez},
  journal={Tumor Biology},
  year={2016},
  volume={37},
  pages={13687-13694}
}
Mutation analysis of epidermal growth factor receptor (EGFR) gene is essential for treatment selection in non-small cell lung cancer (NSCLC). Analysis is usually performed in tumor samples. We evaluated the clinical utility of EGFR analysis in plasma cell-free DNA (cfDNA) from patients under treatment with EGFR inhibitors. We selected 36 patients with NSCLC and EGFR-activating mutations. Blood samples were collected at baseline and during treatment with EGFR inhibitors. Wild-type EGFR, L858R… CONTINUE READING